Episode Details

Send us Fan Mail

Dr. Atul Malhotra, neonatologist and researcher at Monash University in Melbourne, Australia, makes the case that cell therapy for neonatal brain injury is a slow burn that is finally gaining momentum. He shares why tempering expectations doesn't mean losing hope, how regulatory complexity sets stem cells apart from conventional therapies, and why cell therapy may look different for preterm infants with white matter injury versus term infants with HIE.

Support the show

As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.

Enjoy!